Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 9/20 | 0.56 |
| ▸ | RHEB | Q15382 | 2/20 | 0.33 |
| ▸ | PTGES | O14684 | 2/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23914638 | 0.83 | S1PR2 (0.80) | S1PR2RHEB | |
| SCHEMBL23909101 | 0.82 | S1PR2 (0.52) | S1PR2RHEBKCNH2 | |
| SCHEMBL23909082 | 0.82 | S1PR2 (0.57) | S1PR2 | |
| SCHEMBL23909008 | 0.81 | S1PR2 (0.68) | S1PR2KCNH2 | |
| SCHEMBL23908801 | 0.81 | S1PR2 (0.67) | S1PR2RHEBTP53 | |
| SCHEMBL23908858 | 0.80 | S1PR2 (0.75) | S1PR2 | |
| SCHEMBL23908970 | 0.79 | S1PR2 (0.54) | S1PR2RHEBKCNH2 | |
| SCHEMBL23966863 | 0.78 | S1PR2 (0.60) | S1PR2RHEBPDE5A | |
| SCHEMBL23908734 | 0.78 | S1PR2 (0.69) | S1PR2RHEBKCNH2 | |
| SCHEMBL23909119 | 0.75 | S1PR2 (0.54) | S1PR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885RHEB 2911/4885PTGES 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.